Search

Your search keyword '"Sara Piovesan"' showing total 21 results
Start Over Author "Sara Piovesan"
21 results on '"Sara Piovesan"'

1. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

Author

Giada Carolo, Veronica Bernabucci, Luchino Chessa, Maria Luisa Russo, Giorgio Maria Saracco, Marzia Montalbano, Barbara Menzaghi, Giovanni Di Perri, Adriano Lazzarin, Silvia La Monica, Raffaele Bruno, Gian Ludovico Rapaccini, Mario U. Mondelli, Anna Maria Schimizzi, Caterina Pasquazzi, Maurizia Rossana Brunetto, Antonio Craxì, Filomena Morisco, Carmela Lo Guercio, Vania Giacomet, Alessia Giorgini, Mario Masarone, Francesca Paolo Russo, T. Zolfino, Vincenzo Sangiovanni, Alessia Ciancio, Antonella d'Arminio Monforte, Savino Bruno, E.M. Erne, Antonio Gasbarrini, Francesco Castelli, Sergio Novara, G. Nardone, Andrea De Luca, Claudio Maria Mastroianni, Gioacchino Angarano, Chiara Dentone, Renato Maserati, Anna Maria Piscaglia, Tiziana Quirino, Giuseppe Tarantino, M. Lichtner, Antonio Chirianni, Giuseppina Brancaccio, S. Paganin, Alfredo Alberti, Silvia Corradori, Edoardo G. Giannini, Carlo Torti, Chiara Boarini, Raffaele Cozzolongo, Marco Di Stefano, Alessandro Soria, Paolo Tundi, Giovanni Cassola, Debora Angrisani, Antonio Grieco, Cecilia Pravadelli, Giuliano Rizzardini, Roberto Gulminetti, Vincenzo Messina, Maria Rendina, Massimo Pirisi, Irene Cacciola, Roberto Ganga, Raffaella Lionetti, Paolo Calabrese, Laura Ponti, Filomena Simeone, Maurizio Russello, Monica Monti, Nicola Boffa, Pierluigi Tarquini, Franco Capra, Ivo Avancini, Domenico Sansonno, Stefano Fagiuoli, Michele Barone, Giacomo Vecchiet, Salvatore Rizzo, Carlo Federico Perno, Teresa Santantonio, Pierluigi Toniutto, Massimo Zuin, Nicola Caporaso, Alessandra Orlandini, Grazielle Marie Pigozzi, Martina Felder, Antonio Cristaudo, Roberto Cecere, Massimo Marignani, Vincenza Calvaruso, G. Abbati, Domenico Potenza, Maria Chiara Piras, Mario Rizzetto, Serena Cima, Marco delle Monache, Alessio Aghemo, D. Ieluzzi, Guglielmo Borgia, Giampaolo Corti, Paolo Poggio, Manuela Merli, Elena Danieli, Andrea Giacometti, Massimo Andreoni, Antonino Picciotto, Mario Angelico, Benedetta Canovari, Sara Piovesan, Anna Linda Zignego, Antonio Benedetti, Emanuele Durante, Erica Villa, Marcello Persico, Antonio Patrizio Termite, Barbara Coco, Maria Vinci, Lucio Boglione, Cristina Rossi, Paolo Angeli, Massimo Memoli, Maria Teresa Giordani, Massimo De Luca, Luisa Pasulo, Vincenzo Vullo, Mario Melazzini, Attilio Solinas, Pietro Gatti, Michele Guerra, Silvia Martini, Antonio Ascione, Massimo Puoti, Roberto Cauda, Giovanna Onnelli, Silvia Magnani, Salvatore Madonna, Giovanni Raimondo, Marco Tabone, Gloria Taliani, Dante Romagnoli, Aldo Marrone, Umberto Vespasiani Gentilucci, Luca Miele, Marcello Tavio, Andrea Antinori, Giampiero D'Offizi, Mirella Onofrio, Valentina Iodice, Lucio Cosco, Guido Piai, Luca Pani, Francesca Ceccherini Silberstein, Simona Montilla, Marco Lenzi, Luca Fontanella, Alessandro Federico, Carlo Ferrari, Giustino Parruti, Antonio Di Biagio, Gabriella Verucchi, Fabio Marsetti, Michele Milella, Maria Grazia Rumi, Antonio Izzi, Marco Marzioni, Francesca Donato, Vanni Borghi, Mariano Quartini, Massimo Colombo, Michele Imparato, Giovanni Battista Gaeta, P.L. Blanc, Alfredo Di Leo, Nicola Coppola, Alessandro Chiodera, Ivana Maida, Davide Campagnolo, Cinzia Antonini, Antonietta Romano, A. Gianstefani, Katia Falasca, Massimo Levrero, Gaetano Serviddio, Maria Paola Trotta, Olivia Morelli, Salvatore Petta, Elisabetta Teti, Maria Rita Parisi, Pietro Andreone, Ascione, Antonio, De Luca, Massimo, Melazzini, Mario, Montilla, Simona, Trotta, Maria Paola, Petta, Salvatore, Puoti, Massimo, Sangiovanni, Vincenzo, Messina, Vincenzo, Bruno, Savino, Izzi, Antonio, Villa, Erica, Aghemo, Alessio, Zignego, Anna Linda, Orlandini, Alessandra, Fontanella, Luca, Gasbarrini, Antonio, Marzioni, Marco, Giannini, Edoardo G., Craxì, Antonio, Abbati, Giuseppe, Alberti, Alfredo, Andreone, Pietro, Andreoni, Massimo, Angeli, Paolo, Angelico, Mario, Angarano, Gioacchino, Angrisani, Debora, Antinori, Andrea, Antonini, Cinzia, Avancini, Ivo, Barone, Michele, Bruno, Raffaele, Benedetti, Antonio, Bernabucci, Veronica, Blanc, Pier, Boarini, Chiara, Boffa, Nicola, Boglione, Lucio, Borghi, Vanni, Borgia, Guglielmo, Brancaccio, Giuseppina, Brunetto, Maurizia, Cacciola, Irene, Calabrese, Paolo, Calvaruso, Vincenza, Campagnolo, Davide, Canovari, Benedetta, Caporaso, Nicola, Capra, Franco, Carolo, Giada, Cassola, Giovanni, Castelli, Francesco, Cauda, Roberto, Silberstein, Francesca Ceccherini, Cecere, Roberto, Chessa, Luchino, Chiodera, Alessandro, Chirianni, Antonio, Ciancio, Alessia, Cima, Serena, Coco, Barbara, Colombo, Massimo, Coppola, Nicola, Corti, Giampaolo, Cosco, Lucio, Corradori, Silvia, Cozzolongo, Raffaele, Cristaudo, Antonio, Danieli, Elena, Monforte, Antonella D’Arminio, Monache, Marco delle, Del Poggio, Paolo, de Luca, Andrea, Dentone, Chiara, Di Biagio, Antonio, Di Leo, Alfredo, Di Perri, Giovanni, Di Stefano, Marco, D’Offizi, Giampiero, Donato, Francesca, Durante, Emanuele, Erne, Elke, Fagiuoli, Stefano, Falasca, Katia, Federico, Alessandro, Felder, Martina, Ferrari, Carlo, Gaeta, Giovanni Battista, Ganga, Roberto, Gatti, Pietro, Giacomet, Vania, Giacometti, Andrea, Gianstefani, Alice, Giordani, Maria, Giorgini, Alessia, Grieco, Antonio, Guerra, Michele, Gulminetti, Roberto, Ieluzzi, Donatella, Imparato, Michele, Iodice, Valentina, La Monica, Silvia, Lazzarin, Adriano, Lenzi, Marco, Levrero, Massimo, Lichtner, Myriam, Lionetti, Raffaella, Guercio, Carmela Lo, Madonna, Salvatore, Magnani, Silvia, Maida, Ivana, Marignani, Massimo, Marrone, Aldo, Marsetti, Fabio, Martini, Silvia, Masarone, Mario, Maserati, Renato, Mastroianni, Claudio Maria, Memoli, Massimo, Menzaghi, Barbara, Merli, Manuela, Miele, Luca, Milella, Michele, Mondelli, Mario, Montalbano, Marzia, Monti, Monica, Morelli, Olivia, Morisco, Filomena, Nardone, Gaetano, Novara, Sergio, Onnelli, Giovanna, Onofrio, Mirella, Paganin, Simona, Pani, Luca, Parisi, Maria Rita, Parruti, Giustino, Pasquazzi, Caterina, Pasulo, Luisa, Perno, Carlo Federico, Persico, Marcello, Piai, Guido, Picciotto, Antonino, Pigozzi, Grazielle Marie, Piovesan, Sara, Piras, Maria Chiara, Pirisi, Massimo, Piscaglia, Anna Maria, Ponti, Laura, Potenza, Domenico, Pravadelli, Cecilia, Quartini, Mariano, Quirino, Tiziana, Raimondo, Giovanni, Rapaccini, Gian Ludovico, Rendina, Maria, Rizzardini, Giuliano, Rizzetto, Mario, Rizzo, Salvatore, Romagnoli, Dante, Romano, Antonietta, Rossi, Cristina, Rumi, Maria Grazia, Russello, Maurizio, Russo, Francesca Paolo, Russo, Maria Luisa, Sansonno, Domenico Ettore, Santantonio, Teresa Antonia, Saracco, Giorgio, Schimizzi, Anna Maria, Serviddio, Gaetano, Simeone, Filomena, Solinas, Attilio, Soria, Alessandro, Tabone, Marco, Taliani, Gloria, Tarantino, Giuseppe, Tarquini, Pierluigi, Tavio, Marcello, Termite, Antonio, Teti, Elisabetta, Toniutto, Pierluigi, Torti, Carlo, Tundi, Paolo, Vecchiet, Giacomo, Verucchi, Gabriella, Gentilucci, Umberto Vespasiani, Vinci, Maria, Vullo, Vincenzo, Zolfino, Teresa, Zuin, Massimo, Ascione, A, De Luca, M, Melazzini, M, Montilla, S, Trotta, M, Petta, S, Puoti, M, Sangiovanni, V, Messina, V, Bruno, S, Izzi, A, Villa, E, Aghemo, A, Zignego, A, Orlandini, A, Fontanella, L, Gasbarrini, A, Marzioni, M, Giannini, E, Craxi, A, Abbati, G, Alberti, A, Andreone, P, Andreoni, M, Angeli, P, Angelico, M, Angarano, G, Angrisani, D, Antinori, A, Antonini, C, Avancini, I, Barone, M, Bruno, R, Benedetti, A, Bernabucci, V, Blanc, P, Boarini, C, Boffa, N, Boglione, L, Borghi, V, Borgia, G, Brancaccio, G, Brunetto, M, Cacciola, I, Calabrese, P, Calvaruso, V, Campagnolo, D, Canovari, B, Caporaso, N, Capra, F, Carolo, G, Cassola, G, Castelli, F, Cauda, R, Silberstein, F, Cecere, R, Chessa, L, Chiodera, A, Chirianni, A, Ciancio, A, Cima, S, Coco, B, Colombo, M, Coppola, N, Corti, G, Cosco, L, Corradori, S, Cozzolongo, R, Cristaudo, A, Danieli, E, Monforte, A, Monache, M, Del Poggio, P, de Luca, A, Dentone, C, Di Biagio, A, Di Leo, A, Di Perri, G, Di Stefano, M, D'Offizi, G, Donato, F, Durante, E, Erne, E, Fagiuoli, S, Falasca, K, Federico, A, Felder, M, Ferrari, C, Gaeta, G, Ganga, R, Gatti, P, Giacomet, V, Giacometti, A, Gianstefani, A, Giordani, M, Giorgini, A, Grieco, A, Guerra, M, Gulminetti, R, Ieluzzi, D, Imparato, M, Iodice, V, La Monica, S, Lazzarin, A, Lenzi, M, Levrero, M, Lichtner, M, Lionetti, R, Guercio, C, Madonna, S, Magnani, S, Maida, I, Marignani, M, Marrone, A, Marsetti, F, Martini, S, Masarone, M, Maserati, R, Mastroianni, C, Memoli, M, Menzaghi, B, Merli, M, Miele, L, Milella, M, Mondelli, M, Montalbano, M, Monti, M, Morelli, O, Morisco, F, Nardone, G, Novara, S, Onnelli, G, Onofrio, M, Paganin, S, Pani, L, Parisi, M, Parruti, G, Pasquazzi, C, Pasulo, L, Perno, C, Persico, M, Piai, G, Picciotto, A, Pigozzi, G, Piovesan, S, Piras, M, Pirisi, M, Piscaglia, A, Ponti, L, Potenza, D, Pravadelli, C, Quartini, M, Quirino, T, Raimondo, G, Rapaccini, G, Rendina, M, Rizzardini, G, Rizzetto, M, Rizzo, S, Romagnoli, D, Romano, A, Rossi, C, Rumi, M, Russello, M, Russo, F, Russo, M, Sansonno, D, Santantonio, T, Saracco, G, Schimizzi, A, Serviddio, G, Simeone, F, Solinas, A, Soria, A, Tabone, M, Taliani, G, Tarantino, G, Tarquini, P, Tavio, M, Termite, A, Teti, E, Toniutto, P, Torti, C, Tundi, P, Vecchiet, G, Verucchi, G, Gentilucci, U, Vinci, M, Vullo, V, Zolfino, T, and Zuin, M

Subjects
Cyclopropanes, Liver Cirrhosis, Male, Cirrhosis, Dasabuvir, Elderly, Ombitasvir, Paritaprevir, Aged, 80 and over, Anilides, Antiviral Agents, Biomarkers, Carbamates, Female, Hepacivirus, Hepatitis C, Chronic, Humans, Macrocyclic Compounds, Ribavirin, Ritonavir, Sulfonamides, Treatment Outcome, Uracil, Drug Therapy, Combination, Genotype, Cirrhosis, Dasabuvir, Elderly, Ombitasvir, Paritaprevir, Microbiology (medical), Infectious Diseases, Aged, 80 and over, Hepatitis C, Chronic, Drug Therapy, Combination, Microbiology (medical), Infectious Diseases, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, 2-Naphthylamine, Medicine, 030212 general & internal medicine, Valine, General Medicine, 030211 gastroenterology & hepatology, Macrocyclic Compound, medicine.drug, Human, medicine.medical_specialty, Proline, Lactams, Macrocyclic, Settore MED/12 - GASTROENTEROLOGIA, Liver Cirrhosi, Sulfonamide, 03 medical and health sciences, Internal medicine, Decompensation, Hepatitis, Antiviral Agent, Cirrhosi, Hepaciviru, business.industry, Settore MED/09 - MEDICINA INTERNA, Anilide, Biomarker, medicine.disease, chemistry, Carbamate, business
Abstract

Purpose: To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65years. Methods: We collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with cirrhosis due to hepatitis C virus (HCV) Genotype-1 (GT1) or 4 and at high risk of decompensation. GT1-HCV-infected patients received once-daily ombitasvir/paritaprevir, with the pharmacokinetic enhancer ritonavir (25/150/100mg) and twice-daily dasabuvir (250mg) plus Ribavirin (RBV) (OBV/PTV/r + DSV + RBV) for 12 (GT1b) or 24 (GT1a) weeks. Endpoints were to evaluate safety and efficacy, the latter defined as HCV RNA negative 12weeks after the end of treatment (SVR12). Results: Patients who suffered any adverse event (AE) were 74/240 (30.8%); 13/240 (5.4%) discontinued the treatment. A multivariate analysis found albumin < 3.5g/dL (OR 2.04: 95% CI 1.0–4.2, p < 0.05) and hypertension (OR 4.6: 95% CI 2.3–9.2, p < 0.001) as variables independently associated with AE occurrence. The SVR12 was 95% (228/240). Multivariate analysis identified baseline bilirubin < 2mg/dL (OR 4.9: 95% CI 1.17–20.71, p = 0.029) as the only variable independently associated with SVR12. Conclusion: Our findings suggest that OBV/PTV/r + DSV + RBV is safe and effective in real-life use in patients with compensated cirrhosis, HCV-GT1 infection, and age over 65.

Published
2018

2. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study

Author

Alfredo Alberti, Franco Noventa, Sandro Panese, Sara Piovesan, Diego Tempesta, Francesco Paolo Russo, Maurizio Carrara, Luisa Cavalletto, Giada Carolo, Pier Giorgio Scotton, Liliana Chemello, Georgios Anastassopoulos, T. Bertin, Patrizia Burra, Paolo Angeli, Antonio Carlotto, Antonietta Romano, Franco Capra, Valter Vincenzi, Martina Gambato, and Giovanna Scroccaro

Subjects
0301 basic medicine, Liver Cirrhosis, Male, Cirrhosis, Sustained Virologic Response, Hepatocellular carcinoma, medicine.medical_treatment, Advanced liver disease, Direct Acting Antiviral Agents, Hepatitis C, Risk factor, Hepacivirus, Liver transplantation, medicine.disease_cause, Gastroenterology, 0302 clinical medicine, Risk Factors, Prospective Studies, education.field_of_study, Incidence, Liver Neoplasms, Middle Aged, Treatment Outcome, Italy, 030211 gastroenterology & hepatology, Female, medicine.medical_specialty, Carcinoma, Hepatocellular, Population, Antiviral Agents, Risk Assessment, 03 medical and health sciences, Internal medicine, medicine, Humans, education, Aged, Hepatitis, Hepatitis B virus, Hepatology, business.industry, Hepatitis C, Chronic, medicine.disease, digestive system diseases, 030104 developmental biology, Liver function, business
Abstract

Direct-acting antiviral agents (DAAs) are safe and effective in patients with hepatitis C. Conflicting data were reported on the risk of hepatocellular carcinoma (HCC) during/after therapy with DAAs. The aim of this study was to evaluate the incidence of newly diagnosed HCC and associated risk factors in patients with advanced hepatitis C treated with DAAs.The study is based on the NAVIGATORE platform, a prospectively recording database of all patients with hepatitis C receiving DAAs in the Veneto region of Italy. The inclusion criteria were: fibrosis stage ≥F3. The exclusion criteria were: Child-Turcotte-Pugh (CTP)-C, liver transplantation before DAAs, history or presence of HCC, follow-up4 weeks after starting DAAs. A total of 3,917 out of 4,234 consecutive patients were included, with a mean follow-up of 536.2 ± 197.6 days.Overall, HCC was diagnosed in 55 patients. During the first year, HCC incidence was 0.46% (95% CI 0.12-1.17) in F3, 1.49% (1.03-2.08) in CTP-A and 3.61% (1.86-6.31) in CTP-B cirrhotics; in the second year, HCC incidences were 0%, 0.2%, and 0.69%, respectively. By multivariate analysis, HCC was significantly associated with an aspartate aminotransferase to platelet ratio ≥2.5 (hazard ratio [HR] 2.03; 95% CI 1.14-3.61; p = 0.016) and hepatitis B virus infection (HR 3.99; 1.24-12.91; p = 0.021). Failure to achieve a sustained virological response was strongly associated with development of HCC (HR 9.09; 5.2-16.1; p = 0.0001). A total of 29% of patients with HCC had an aggressive tumor, often seen in the early phase of treatment.These data, obtained in a large, prospective, population-based study, indicate that in patients with advanced hepatitis C receiving DAAs, the risk of "de novo" hepatocarcinoma during the first year is not higher, and might be lower, than that of untreated patients. The risk further declines thereafter. Early hepatocarcinoma appearance may reflect pre-existing, microscopic, undetectable tumors.Hepatocellular carcinoma is one of the complications of hepatitis C related cirrhosis. Treating patients with advanced hepatitis C with the new interferon-free direct-acting antiviral agents has been associated with improvement in liver function and survival, while more conflicting data have been reported regarding the risk of hepatocellular carcinoma. We report the results of a prospective population study on the incidence of newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with direct-acting antiviral agents, clearly indicating that the residual hepatocellular carcinoma risk is reduced and declines progressively with time after a sustained virological response. Development of a liver tumor during/after therapy was associated with known risk factors and with virological failure.

Published
2017

3. The evolution of the therapeutic strategy in hepatitis C: Features of sofosbuvir and indications

Author

Sara Piovesan and Alfredo Alberti

Subjects
Sofosbuvir, Combination therapy, Genotype, Hepatitis C virus, Hepacivirus, Guidelines, Pharmacology, medicine.disease_cause, Virus Replication, Antiviral Agents, Virus, chemistry.chemical_compound, Interferon, Pegylated interferon, medicine, Humans, Hepatology, business.industry, Ribavirin, Gastroenterology, Hepatitis C, Hepatitis C, Chronic, medicine.disease, Virology, chemistry, Drug Therapy, Combination, business, Uridine Monophosphate, medicine.drug
Abstract

The treatment of chronic hepatitis C virus infection is rapidly evolving with the entry into the therapeutic armamentarium of a series of new and highly effective direct antiviral agents, targeted to the different virus structures involved in hepatitis C virus replication and assembly. Sofosbuvir is considered, without controversies, the most promising single direct antiviral agent in the current scenario. The pharmacological properties of sofosbuvir allow a single oral daily administration and ensure a favourable drug–drug interaction profile, compared to other direct antiviral agents. Clinical development of sofosbuvir has been conducted with the strategy of positioning it as the backbone drug of several combination regimes, including triple therapy with pegylated interferon and ribavirin, but also IFN-free regimen with ribavirin alone as well as with complementary direct antiviral agents directed against other virus targets. Based on available data and International guidelines sofosbuvir is indicated in combination with pegylated interferon and ribavirin in patients infected with hepatitis C virus 1 to 6 that can take interferon, and this regimen is particularly efficacious in those who have not received any previous antiviral treatment. The pangenotypic activity, excellent safety (even in advanced liver disease) make sofosbuvir the ideal backbone for combination therapy in all hepatitis C virus patients subgroups, the limiting factors being safety and tolerability of the combined direct antiviral agent rather than those of sofosbuvir itself.

Published
2014
Full Text
View/download PDF

4. HCC recurrence under all-oral DAAs-based antiviral therapy in HCV-infected patients: data from Navigatore web platform

Author

Franco Capra, M. De Bona, Veronica Paon, P. Angeli, Alfredo Alberti, Irene Franceschet, Antonietta Romano, C. Manuppelli, Sara Piovesan, L. Lomonaco, Francesco Russo, M.T. Giordani, S. Storato, G. Anastassopoulos, Pierangelo Rovere, Alberto Zanetto, Martina Gambato, P. Burra, and Antonio Carlotto

Subjects
Oncology, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, Hepatology, business.industry, Internal medicine, Antiviral therapy, Medicine, 030211 gastroenterology & hepatology, 030230 surgery, business
Published
2018
Full Text
View/download PDF

5. THU-131-Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: A real-life study from the NAVIGATORE Lombardia and Veneto Networks

Author

Sara Piovesan, Franco Noventa, Pietro Lampertico, Antonio Carlotto, Paolo Bonfanti, Alessio Aghemo, Canio Carriero, Alessandro Soria, Simona Landonio, Pierangelo Rovere, Filippo Viviani, Angiola Spinetti, Alessia Giorgini, Roberta Soffredini, Maurizio Carrara, Alessia Zoncada, Lorenzo Morini, Pietro Pozzoni, Federico Gatti, Giada Carolo, Franco Capra, Elisabetta Degasperi, Pier Giorgio Scotton, Maria Cristina Vinci, Andrea Lombardi, Paolo Angeli, Riccardo Centenaro, Luisa Pasulo, Alfredo Alberti, Franco Maggiolo, Massimo Puoti, Stefano Fagiuoli, Francesco Russo, and Stefania Paolucci

Subjects
medicine.medical_specialty, Hepatology, Chronic hepatitis, business.industry, Medicine, business, Intensive care medicine, DIRECT ACTING ANTIVIRALS, Life study, Sofosbuvir / velpatasvir / voxilaprevir
Published
2019
Full Text
View/download PDF

6. SAT-262-Long-term liver function outcome and related risk factors in HCV cirrhotic patients treated with direct-acting antiviral therapy: Results from the Navigatore platform in Veneto-Italy

Author

Sara Piovesan, Anna Maria Cattelan, Paolo Angeli, Francesco Russo, Sandro Panese, Franco Noventa, Veronica Paon, Irene Franceschet, S. Lobello, Martina Gambato, Giada Carolo, Patrizia Burra, Liliana Chemello, Antonietta Romano, Bertin Tosca, Caterina Pozzan, Valter Vincenzi, and Alfredo Alberti

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, medicine, Antiviral therapy, Liver function, business, Outcome (game theory), Direct acting, Term (time)
Published
2019
Full Text
View/download PDF

7. Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C: Fact or fiction?

Author

Alfredo Alberti and Sara Piovesan

Subjects
Liver Cirrhosis, Oncology, medicine.medical_specialty, Carcinoma, Hepatocellular, Antiviral Agents, 03 medical and health sciences, 0302 clinical medicine, Chronic hepatitis, Risk Factors, Internal medicine, medicine, Humans, In patient, direct antiviral agents, Hepatitis C, hepatocellular carcinoma, Hepatology, Prospective cohort study, neoplasms, business.industry, Incidence, Incidence (epidemiology), Liver Neoplasms, Hepatitis C, Chronic, medicine.disease, digestive system diseases, Surgery, Homogeneous, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, 030211 gastroenterology & hepatology, Neoplasm Recurrence, Local, business, Liver cancer
Abstract

Therapy of hepatitis C has been revolutionized by Direct Antiviral Agents. These drugs are safe and efficacious in all infected patients, including those with advanced, or decompensated cirrhosis, and are currently largely used in such cases in clinical practice worldwide. It was therefore cause of great concern the publication of two reports suggesting that treatment with DAAs could increase the risk of hepatocellular carcinoma in cirrhotic patients, particularly in those receiving antiviral therapy after having been cured for an HCC. These reports have generated a great and controversial debate and have been followed by a series of other publications not confirming such increased risk. This article summarizes published studies assessing the relation between DAA therapy and HCC in two different clinical setting: HCC recurrence in patients with an history of cured HCC and "de novo" HCC occurrence in patients without previous HCC. Rates of HCC recurrence after DAAs were extremely variable in different studies, reflecting great heterogeneity of this clinical setting. Data on "de novo" HCC incidence were more homogeneous and suggest that treatment with DAAs is not modifying the risk of developing HCC in the first 6-12 months. The possibility that treatment with DAAs may favour tumour growth and spread in individual patients with active HCC foci is suggested by some observations but remains unproven. There is clearly a need for prospective studies designed to better define these issues.

Published
2017

8. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel

Author

Carlo Federico Perno, Elisabetta Degasperi, Stefano Fagiuoli, Vincenza Calvaruso, Salvatore Petta, Raffaele Bruno, Alessia Ciancio, Giovanni Battista Gaeta, Giovanni Raimondo, Carlo Ferrari, Anna Linda Zignego, Massimo Andreoni, Massimo Puoti, Stefano Bonora, Giovanni Di Perri, Gloria Taliani, Pietro Andreone, Alfredo Alberti, Maurizia Rossana Brunetto, Vito Di Marco, Erica Villa, Sara Piovesan, Alessio Aghemo, Mauro Viganò, Francesca Ceccherini-Silberstein, Francesco Paolo Russo, Savino Bruno, Ugo Trama, Adriano M. Pellicelli, Antonio Craxì, Gianpiero D'Offizi, Piero Colombatto, Nicola Caporaso, Valeria Cento, Viganò, Mauro, Perno, Carlo Federico, Craxì, Antonio, Aghemo, Alessio, Alberti, Alfredo, Andreone, Pietro, Andreoni, Massimo, Bonora, Stefano, Brunetto, Maurizia Rossana, Bruno, Raffaele, Bruno, Savino, Calvaruso, Vincenza, Caporaso, Nicola, Ceccherini-Silberstein, Francesca, Cento, Valeria, Ciancio, Alessia, Colombatto, Piero, Degasperi, Elisabetta, Di Marco, Vito, Di Perri, Giovanni, D'offizi, Gianpiero, Fagiuoli, Stefano, Ferrari, Carlo, Gaeta, Giovanni Battista, Pellicelli, Adriano, Petta, Salvatore, Piovesan, Sara, Puoti, Massimo, Raimondo, Giovanni, Russo, Francesco Paolo, Taliani, Gloria, Trama, Ugo, Villa, Erica, Zignego, Anna Linda, Savino, Bruno, Vito, Marco, D'Offizi, Gianpiero, Russo, FRANCESCO PAOLO, Gaeta, G. B., Viganã², M., Perno, C., Craxi, A., Calvaruso, V, Di Marco, V, Petta, S, Vigano, M, Perno, C, Craxi, A, Aghemo, A, Alberti, A, Andreone, P, Andreoni, M, Bonora, S, Brunetto, M, Bruno, R, Bruno, S, Caporaso, N, Ceccherini-Silberstein, F, Cento, V, Ciancio, A, Colombatto, P, Degasperi, E, Di Perri, G, D'Offizi, G, Fagiuoli, S, Ferrari, C, Gaeta, G, Pellicelli, A, Piovesan, S, Puoti, M, Raimondo, G, Russo, F, Taliani, G, Trama, U, Villa, E, and Zignego, A

Subjects
Liver Cirrhosis, Direct-acting antiviral agent, Fibrosi, Hepacivirus, Chronic liver disease, medicine.disease_cause, Clinical knowledge, Virological response, 0302 clinical medicine, 80 and over, 030212 general & internal medicine, Chronic, Antiviral treatment, Cirrhosis, Direct-acting antiviral agents, Hepatitis C, RAV, Treatment failure, Aged, 80 and over, Gastroenterology, Hepatology, Middle Aged, Viral Load, Settore MED/07 - Microbiologia e Microbiologia Clinica, Italy, Liver, Combination, 030211 gastroenterology & hepatology, Drug Therapy, Combination, Human, Adult, medicine.medical_specialty, Consensus, Hepatitis C virus, Liver Cirrhosi, Consensu, Antiviral Agents, Unmet needs, 03 medical and health sciences, Young Adult, Drug Therapy, Internal medicine, medicine, Humans, Intensive care medicine, Aged, Antiviral Agent, Hepaciviru, Cirrhosi, business.industry, Hepatitis C, Chronic, medicine.disease, Virology, Fibrosis, Position paper, business
Abstract

Hepatitis C virus (HCV) infection remains one of the main causes of chronic liver disease worldwide. The advent of direct-acting antivirals (DAAs) has significantly improved the course of patients with chronic HCV infection (CHC), due to the ability of these drugs to achieve high rates of sustained virological response (SVR). These exceedingly high rates of SVR and the excellent safety data have been confirmed in real life practice. Evolving guidelines have been issued by national and international scientific societies in accordance with the progression of clinical knowledge and the availability of new DAAs. These recommendations, however, may not be applied universally because of delays in drugs reimbursability in different countries and because some National Health Systems identify only patients with advanced disease as a treatment priority. Italy in this regard is a prototype about DAAs treatment of CHC patients. With the aim to assess the Italian treatment experience with DAAs and to respond to unmet needs in treatment optimization of antiviral therapy in specific settings of CHC patients, a group of Italian experts met in Stresa in February 2017. The summary of the considerations arising from this two-day meeting and some statements regarding a few open issues are reported in this position paper.

Published
2017

9. Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto Networks

Author

Pietro Pozzoni, Maria Cristina Vinci, Andrea Lombardi, Pietro Lampertico, Paolo Angeli, Alessio Aghemo, M. Puoti, F. Maggiolo, A. Carlotto, Simona Landonio, Sara Piovesan, Francesca Gatti, P. Scotton, Francesco Russo, Angiola Spinetti, Stefania Paolucci, Giada Carolo, Franco Noventa, Franco Capra, Stefano Fagiuoli, P.A. Rovere, Lorenzo Morini, Alessia Giorgini, P. Bonfanti, C. Carriero, F. Viviani, Elisabetta Degasperi, A. Zoncada, Roberta Soffredini, Riccardo Centenaro, Luisa Pasulo, Alfredo Alberti, Alessandro Soria, and Maurizio Carrara

Subjects
medicine.medical_specialty, Hepatology, Chronic hepatitis, business.industry, Gastroenterology, Medicine, business, Intensive care medicine, Life study, DIRECT ACTING ANTIVIRALS, Sofosbuvir / velpatasvir / voxilaprevir
Published
2019
Full Text
View/download PDF

10. Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients

Author

Sara Piovesan, Roberta Russo, Pierluigi Toniutto, Achille Iolascon, Lucia De Franceschi, Francesco Michelangelo Turrini, Francesca Lupo, D. Ieluzzi, Alessandro Matte, Angela Siciliano, Alfredo Alberti, Elena Raffetti, Francesco Donato, Denis Dissegna, Valeria Zuliani, Giovanna Fattovich, Lupo, Francesca, Russo, Roberta, Iolascon, Achille, Ieluzzi, Donatella, Siciliano, Angela, Toniutto, Pierluigi, Matté, Alessandro, Piovesan, Sara, Raffetti, Elena, Turrini, Francesco, Dissegna, Deni, Donato, Francesco, Alberti, Alfredo, Zuliani, Valeria, Fattovich, Giovanna, and De Franceschi, Lucia

Subjects
0301 basic medicine, Ineffective erythropoiesis, chronic hepatitis C, first-generation protease inhibitors, microparticles, spherocytic-like anaemia, Adult, Aged, Antiviral Agents, Drug Monitoring, Drug Therapy, Combination, Erythrocyte Indices, Erythrocyte Membrane, Erythropoiesis, Female, Humans, Interferon-alpha, Male, Middle Aged, Polymorphism, Single Nucleotide, Proline, Protease Inhibitors, Pyrophosphatases, Ribavirin, Treatment Outcome, Anemia, Hepatitis C, Chronic, Oligopeptides, Hepatology, medicine.disease_cause, Telaprevir, first-generation protease inhibitor, chemistry.chemical_compound, 0302 clinical medicine, hemic and lymphatic diseases, Chronic, Single Nucleotide, Hepatitis C, microparticle, Combination, ITPA, medicine.drug, Biology, 03 medical and health sciences, Drug Therapy, Boceprevir, medicine, Polymorphism, Red Cell, medicine.disease, 030104 developmental biology, chemistry, Immunology, 030215 immunology
Abstract

Background & Aims The addition of protease inhibitors, boceprevir (BOC) or telaprevir (TRV), to peg-interferon and ribavirin (PR) increases the incidence of anaemia in patients with chronic hepatitis C virus (HCV) infection. Although genetic variants in inosine triphosphatase (ITPA) gene have been linked to the haemolytic anaemia induced by PR, the mechanism sustaining severe anaemia during triple therapy is still unknown. This study aims to elucidate the molecular mechanisms underlying anaemia in chronic HCV patients with combined therapy. Methods We studied 59 patients with chronic HCV genotype-1: 29 treated with TRV/PR and 30 with BOC/PR. We evaluated biochemical and haematological parameters, red cell index at baseline, 4, 12, 16 and 24 weeks of treatment; in a subgroup, we performed functional studies: osmotic fragility, red cell membrane protein separation, mass spectrometry analysis, quantification of erythroid microparticles release. IL28B and ITPA polymorphisms were also evaluated. Results We found early acute normochromic normocytic haemolytic anaemia (4–8 weeks) followed by a late macrocytic hypo-regenerative anaemia with inappropriate low reticulocyte count (12–24 weeks). Studies on red cells revealed: (i) presence of spherocytes; (ii) increased osmotic fragility; (iii) abnormalities in red cell membrane protein composition; (iv) reduced membrane-cytoskeleton stability; (v) increased release of erythroid microparticles. ITPA polymorphisms impacted only the early phase of anaemia. Conclusions The bimodal pattern of anaemia in chronic HCV patients on triple therapy might be because of acquired spherocytic-like anaemia in the early phase, followed by hyporegenerative anaemia, most likely related to the combined effects of PR and TRV or BOC on erythropoiesis.

Published
2016

11. Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: A report from the Lombardia Network and Navigator Study Group

Author

Stefano Fagiuoli, Sandro Panese, Elisabetta Degasperi, Sara Piovesan, Angelo Rossini, Paolo Angeli, Angelo Pan, Serena Zaltron, Tiziana Quirino, Luisa Pasulo, Pietro Lampertico, Silvia Fargion, Alfredo Alberti, Roberto Gulminetti, Alessio Aghemo, Giada Carolo, Massimo Zuin, A. Colli, Valter Vincenzi, A. Corbellini, P. Scotton, Francesco Paolo Russo, Liliana Chemello, M.G. Rumi, P.A. Rovere, S. Lobello, Franco Capra, Patrizia Burra, C. Uberti Foppa, Giuliano Rizzardini, Paolo Fabris, F. Maggiolo, G. Carlotto, Paolo Grossi, Paolo Sacchi, M. Puoti, and Anna Maria Cattelan

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, business, DIRECT ACTING ANTIVIRALS
Published
2018
Full Text
View/download PDF

12. Effectiveness and safety of DAA treatment for recurrent hepatitis C after liver transplantation: The NAVIGATOR Lombardia-Veneto network

Author

Angelo Rossini, A. Corbellini, Serena Zaltron, Liliana Chemello, Francesco Paolo Russo, P. Scotton, Federica Invernizzi, C. Uberti Foppa, Paolo Sacchi, Franco Capra, Anna Maria Cattelan, Angelo Pan, Silvia Fargion, Pietro Lampertico, Roberto Gulminetti, Alessio Aghemo, Massimo Zuin, G. Carlotto, S. Lobello, Sandro Panese, Lino Belli, Giuliano Rizzardini, M.G. Rumi, M. Puoti, Stefano Fagiuoli, Giada Carolo, Luisa Pasulo, Valter Vincenzi, P.A. Rovere, Paolo Angeli, Paolo Fabris, Patrizia Burra, F. Maggiolo, Tiziana Quirino, Alfredo Alberti, Paolo Grossi, and Sara Piovesan

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, medicine.medical_treatment, Gastroenterology, medicine, Liver transplantation, Recurrent hepatitis, business
Published
2018
Full Text
View/download PDF

16. F-25 Prospective validation of noninvasive methods to assess liver fibrosis in HCV patients after liver transplantation (LT)

Author

Sara Piovesan, Marco Senzolo, Giacomo Germani, G. Cabrelle, P. Burra, Alfredo Alberti, Giacomo Zanus, U. Cillo, E. De Martin, E. Nadal, Alessandro Vitale, Martina Gambato, Anna Chiara Frigo, and Francesco Russo

Subjects
Pathology, medicine.medical_specialty, Hepatology, business.industry, Liver fibrosis, medicine.medical_treatment, Gastroenterology, medicine, Liver transplantation, business
Published
2012
Full Text
View/download PDF

17. Acquired spherocytic like anemia combined with ineffective erythropoiesis sustains anemia in patients with chronic hepatitis C infection receiving telaprevir or boceprevir-based triple therapy

Author

Valeria Zuliani, Alfredo Alberti, Francesco Donato, Sara Piovesan, Roberta Russo, Pierluigi Toniutto, Franco Turrini, L De Franceschi, Achille Iolascon, D. Ieluzzi, Elena Raffetti, Francesca Lupo, Alessandro Matte, Angela Siciliano, and Giovanna Fattovich

Subjects
Ineffective erythropoiesis, Hepatology, Anemia, business.industry, Gastroenterology, Pharmacology, medicine.disease, medicine.disease_cause, Virology, In vitro, Telaprevir, chemistry.chemical_compound, Liver disease, chemistry, Boceprevir, medicine, Receptor, business, Intracellular, medicine.drug
Abstract

s / Digestive and Liver Disease 47S (2015) e1–e18 e15 replication, in its presence the inhibition exerted by 17 -estradiol was reverted in a dose-dependent manner. Conclusions: In vitro, 17 -estradiol is able to block HCV infection, likely by modulation of intracellular pathways following binding to the estradiol receptor, whose activation leads to an antiviral state. http://dx.doi.org/10.1016/j.dld.2015.01.034

Published
2015
Full Text
View/download PDF

18. P1158 EFFICACY AND SAFETY OF BOCEPREVIR-BASED THERAPY IN HCVG1 TREATMENT-EXPERIENCED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS: THE ITALIAN AND SPANISH NPP EARLY ACCESS PROGRAM

Author

Javier Crespo, B. Ruiz Antoran, Xavier Forns, Patrick Maisonneuve, J.L. Calleja, I. Fermandez, C. Fernández-Rodríguez, J. de la Revilla, Francesco Mazzotta, Sergio Babudieri, Maurizio Russello, Juan Manuel Pascasio, Carlo Magni, Al Zignego, F. Gea, A. Licata, Ramón Pérez-Álvarez, Maximino Delgado, Savino Bruno, Massimo Zuin, T. Santantonio, M. Rizzetto, Alfredo Alberti, Alberto Colombo, J.M. Navarro, Joaquín Arenas, V. Di Marco, C. Colletta, F. Farina, Maurizio Koch, Simona Bollani, Sara Piovesan, M. Caremani, Mario Pirisi, Manuel Romero-Gómez, Marco Massari, Rafael Bárcena, J.R. Larrubia, Antonio Craxì, A. Ciancio, and Alessandra Mangia

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Hepatitis C, medicine.disease, Advanced fibrosis, Treatment experienced, chemistry.chemical_compound, chemistry, Boceprevir, Medicine, business, Intensive care medicine
Published
2014
Full Text
View/download PDF

19. Efficacy and safety of Boceprevir-based therapy in HCVG1 treatment-experienced patients with advanced fibrosis/cirrhosis: Italian NPP survey

Author

Al Zignego, Marco Massari, E. Marchionne, A. Traverso, Luigi Muratori, V. Di Marco, Alberto Colombo, Simona Landonio, Gaetano Serviddio, Valeria Piazzolla, A. Moretti, Sergio Babudieri, A. Licata, Alessia Ciancio, Massimo Zuin, Francesco Mazzotta, Mario Rizzetto, Maurizio Russello, Teresa Santantonio, S. Fangazio, L. Cavalletto, Simona Bollani, Vincenza Calvaruso, F. Farina, C. Colletta, Antonio Craxì, Carlo Magni, Savino Bruno, Sara Piovesan, M. Caremani, and Alessandra Mangia

Subjects
medicine.medical_specialty, Hepatology, business.industry, Infectious disease (medical specialty), Family medicine, Gastroenterology, medicine, business, Treatment experienced, Advanced fibrosis
Abstract

S. Bruno1, S. Bollani1, A.L. Zignego2, V. Calvaruso3, C. Magni4, S. Landonio4, M. Rizzetto5, A. Ciancio5, A. Mangia6, V. Piazzolla6, M. Caremani7, S. Piovesan8, L. Cavalletto9, S. Babudieri9, A. Moretti 10, C. Colletta11, M. Massari12, S. Fangazio13, F. Mazzotta14, L. Muratori15, A.E. Colombo16, M. Zuin17, A. Traverso18, T. Santantonio19, F. Farina20, E. Marchionne21, G. Serviddio22, M. Russello23, A. Licata24, A. Craxi3, V. Di Marco3 1 Internal Medicine, AO Fatebenefratelli e Oftalmico, Milano, Italy 2 Internal Medicine, Universita di Firenze, Italy 3 Gastroenterology, Universita di Palermo, Italy 4 Infectiuos Diseases, Ospedale Sacco, Milano, Italy 5 Gastroenterology, Universita di Torino, Turin, Italy 6 Liver Unit, IRCCS Casa del Sollievo e della Sofferenza, San Giovanni Rotondo, Italy 7 Infectious Diseases, Azienda Ospedaliera, Arezzo, Italy 8 Internal Medicine, Universita di Padova, Italy 9 Infectious Disease, Universita di Sassari, Italy 10 Gastroenterology, San Filippo Neri, Roma, Italy 11 Internal Medicine, COQ Ospedale Madonna del Popolo, Omegna, Italy 12 Infectious Diseases, IRCCS – ASMN Reggio Emilia, Italy 13 Internal Medicine, Universita di Novara, Italy 14 Infectious Diseases, Azienda Ospedaliera, Siena, Italy 15 Internal Medicine, Universita di Bologna, Italy 16 Gastroenterology, Ospedale S. Anna, Como, Italy 17 Internal Medicine, Universita di Milano, Italy 18 Infectious Disease, AOU, Parini, Aosta, Italy 19 Infectious Diseases, Universita di Foggia, Italy 20 Infectious Diseases, Ospedale Ca Foncello, Treviso, Italy 21 Infectious Diseases, AOU Ospedali Riuniti, Ancona, Italy 22 Internal Medicine, Universita di Foggia, Italy 23 Liver Unit, ARNAS Garibaldi, Catania, Italy 24 Liver Unit, Universita di Palermo, Italy

Published
2014
Full Text
View/download PDF

20. Novel biocompatible chitosan decorated single-walled carbon nanotubes (SWNTs) for biomedical applications: theoretical and experimental investigations

Author

Marta Roldo, Paul A. Cox, Dimitrios G. Fatouros, James R. Smith, and Sara Piovesan

Subjects
Materials science, Magnetic Resonance Spectroscopy, Cell Survival, Binding energy, Molecular Conformation, General Physics and Astronomy, chemistry.chemical_element, Nanotechnology, Biocompatible Materials, Carbon nanotube, Pharmacy, Molecular Dynamics Simulation, Microscopy, Atomic Force, law.invention, Chitosan, chemistry.chemical_compound, Molecular dynamics, law, Materials Testing, Side chain, Humans, Physical and Theoretical Chemistry, Blood Coagulation, Micelles, chemistry.chemical_classification, Aqueous solution, Molecular Structure, Nanotubes, Carbon, technology, industry, and agriculture, Biomedical Sciences, Water, Polymer, chemistry, Thermodynamics, Caco-2 Cells, Carbon
Abstract

Molecular mechanics and molecular dynamics simulations have been employed to characterise the interactions between SWNTs and biocompatible amphililic derivatives of chitosan, namely N-butyl-O-sulfate chitosan (NBSC), N-octyl-O-sulfate chitosan (NOSC) and N-palmitoyl-O-sulfate chitosan (NPSC). The computational simulations have shown that the affinity of the polymer for the hydrophobic surface of the nanotubes depends on the length of the chitosan hydrophobic pendant chain. Longer chains have a higher flexibility and therefore a better ability to wrap around the nanotubes. To underpin the theoretical calculations, experimental studies revealed that NPSC exhibits highest affinity for SWNTs with up to 66.9 ± 19.7% SWNTs stably suspended in an aqueous environment; this affinity was confirmed by the calculated binding energy of five polymer chains with a SWNT that was found to be -300.93 kcal mol(-1), the highest amongst the three polymers studied. Furthermore, the high value of cell viability after incubation with NPSC indicates that this is a good candidate for the preparation of biocompatible SWNTs dipersions that could be used in biomedical and pharmaceutical applications.

Full Text
View/download PDF

21. Liver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection.

Author

Parisi SG, Basso M, Mengoli C, Scaggiante R, Andreis S, Franzetti MM, Cattelan AM, Zago D, Cruciani M, Andreoni M, Piovesan S, Palù G, and Alberti A

Abstract

Background: Human immunodeficiency virus (HIV) may be directly responsible for liver damage but there are contrasting data regarding the influence of detectable plasma viremia. We analyzed the influence of plasma HIV RNA (pHIV) detectability and of other clinical and viro-immunological variables on liver stiffness (LS) measurement in adult immunocompetent HIV-monoinfected patients and in patients coinfected with hepatitis C virus (HCV)., Methods: Logistic regression analysis was performed using the value of LS>7.1 kPa as the dependent variable. A linear regression model was applied using LS measurement after log 10 transformation (lkpa) as the dependent variable and we analyzed the predicted values versus the observed lkpa values; pHIV was classified as detectable or undetectable in the 12- and 36-month study periods before LS measurement., Results: We studied 251 patients (178 with HIV monoinfection), most of whom were on antiviral treatment; 36-month study time was available for 154 subjects. The mean CD4+ cell count was 634 cells/mm 3 in HIV-monoinfected patients and 606 cells/mm 3 in coinfected patients. No difference in LS was found between patients with detectable or undetectable pHIV in either the 12- or the 36-month study period before transient elastography. The mean LS was higher in HIV/HCV coinfected patients (P<0.0001) than in the HIV-monoinfected subjects; lkpa was positively correlated with HCV coinfection (P<0.0001) and aspartate aminotransferase levels (P<0.0001). Detectable pHIV failed to reach significance. Eight HIV-monoinfected patients had a predicted LS measurement lower than the observed one, while eight patients had the opposite result., Conclusion: LS was not correlated with ongoing HIV replication during the 12- and 36-month study periods in immunocompetent HIV-monoinfected and HIV/HCV-coinfected patients., Competing Interests: Conflict of Interest: None

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results